<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Astrazeneca Plc — News on 6ix</title>
<link>https://6ix.com/company/astrazeneca-plc</link>
<description>Latest news and press releases for Astrazeneca Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/astrazeneca-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e04d78dffbe2df125f16.webp</url>
<title>Astrazeneca Plc</title>
<link>https://6ix.com/company/astrazeneca-plc</link>
</image>
<item>
<title>BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older</title>
<link>https://6ix.com/company/astrazeneca-plc/news/breztri-approved-in-the-us-for-asthma-as-first-and-only-triple-therapy-for-patients-12-years-of-age-and-older</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/breztri-approved-in-the-us-for-asthma-as-first-and-only-triple-therapy-for-patients-12-years-of-age-and-older</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>WILMINGTON, Del., April 28, 2026--AstraZeneca’s fixed-dose triple-combination therapy BREZTRI Aerosphere® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in the US for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older. BREZTRI is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines with a long-acting muscarinic antagonist (LAMA). BREZTRI (320/18/9.6μg) was app</description>
</item>
<item>
<title>Breztri approved in the US for asthma</title>
<link>https://6ix.com/company/astrazeneca-plc/news/breztri-approved-in-the-us-for-asthma</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/breztri-approved-in-the-us-for-asthma</guid>
<pubDate>Tue, 28 Apr 2026 06:00:00 GMT</pubDate>
<description>AstraZeneca's Breztri Aerosphere has received US FDA approval for the maintenance treatment of asthma in patients aged 12 and older, marking its second indication beyond COPD. This single-inhaler triple therapy, combining budesonide, glycopyrrolate, and formoterol fumarate, demonstrated statistically significant and clinically meaningful improvements in lung function compared to dual ICS/LABA therapy in the Phase III KALOS and LOGOS trials. Breztri, previously approved for COPD in 2020 and presc</description>
</item>
<item>
<title>Saphnelo self-administration approved in the US</title>
<link>https://6ix.com/company/astrazeneca-plc/news/saphnelo-self-administration-approved-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/saphnelo-self-administration-approved-in-the-us</guid>
<pubDate>Mon, 27 Apr 2026 06:00:00 GMT</pubDate>
<description>AstraZeneca's Saphnelo has received US FDA approval for subcutaneous self-administration via a new autoinjector, the Saphnelo Pen, for adult patients with systemic lupus erythematosus on top of standard therapy. This approval, based on positive Phase III TULIP-SC trial results demonstrating significant disease activity reduction, offers greater flexibility and convenience for patients, building on the over 40,000 patients globally already treated with Saphnelo IV. AstraZeneca will pay Bristol-My</description>
</item>
<item>
<title>I CAN PhIII interim analysis met primary endpoint</title>
<link>https://6ix.com/company/astrazeneca-plc/news/i-can-phiii-interim-analysis-met-primary-endpoint</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/i-can-phiii-interim-analysis-met-primary-endpoint</guid>
<pubDate>Tue, 21 Apr 2026 06:00:00 GMT</pubDate>
<description>AstraZeneca announced positive high-level results from the I CAN Phase III trial for Ultomiris (ravulizumab) in adults with immunoglobulin A nephropathy (IgAN), showing a statistically significant and clinically meaningful reduction in proteinuria at week 34. The drug demonstrated rapid reduction as early as week 10, supporting its potential as a disease-modifying treatment by inhibiting the terminal C5 complement. The safety profile was consistent with known Ultomiris data, and the company plan</description>
</item>
<item>
<title>Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD</title>
<link>https://6ix.com/company/astrazeneca-plc/news/tozorakimab-met-primary-endpoint-in-phase-iii-miranda-trial-in-patients-with-copd</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/tozorakimab-met-primary-endpoint-in-phase-iii-miranda-trial-in-patients-with-copd</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>WILMINGTON, Del., April 20, 2026--Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity.</description>
</item>
<item>
<title>IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer</title>
<link>https://6ix.com/company/astrazeneca-plc/news/imfinzir-durvalumab-imjudor-tremelimumab-actl-improves-pfs-in-early-liver-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/imfinzir-durvalumab-imjudor-tremelimumab-actl-improves-pfs-in-early-liver-cancer</guid>
<pubDate>Thu, 02 Apr 2026 11:00:00 GMT</pubDate>
<description>WILMINGTON, Del., April 02, 2026--Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization.</description>
</item>
<item>
<title>Imfinzi+Imjudo improves PFS in early liver cancer</title>
<link>https://6ix.com/company/astrazeneca-plc/news/imfinziimjudo-improves-pfs-in-early-liver-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/imfinziimjudo-improves-pfs-in-early-liver-cancer</guid>
<pubDate>Thu, 02 Apr 2026 06:00:00 GMT</pubDate>
<description>AstraZeneca announced positive high-level results from the EMERALD-3 Phase III trial, showing that Imfinzi plus Imjudo combined with lenvatinib and transarterial chemoembolisation (TACE) demonstrated a statistically significant improvement in progression-free survival for patients with unresectable hepatocellular carcinoma eligible for embolisation, compared to TACE alone. The combination also showed a trend toward improved overall survival at this interim analysis, and the trial will continue t</description>
</item>
<item>
<title>Total Voting Rights and Admission of Shares</title>
<link>https://6ix.com/company/astrazeneca-plc/news/total-voting-rights-and-admission-of-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/total-voting-rights-and-admission-of-shares-1</guid>
<pubDate>Wed, 01 Apr 2026 14:00:00 GMT</pubDate>
<description>AstraZeneca PLC has announced that as of March 31, 2026, its total voting rights stand at 1,550,980,823 ordinary shares, with no shares held in treasury. The company also reported the admission of 491 further ordinary shares of $0.25 each to trading on the London Stock Exchange's Main Market, bringing the total issued securities to 1,550,980,823. These newly admitted shares, issued between March 20 and March 31, 2026, under employee share schemes, are fully fungible with existing ordinary shares</description>
</item>
<item>
<title>Efzimfotase alfa Ph3 program show positive results</title>
<link>https://6ix.com/company/astrazeneca-plc/news/efzimfotase-alfa-ph3-program-show-positive-results</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/efzimfotase-alfa-ph3-program-show-positive-results</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>AstraZeneca PLC announced positive results from its global Phase III clinical programme for efzimfotase alfa in hypophosphatasia (HPP), a rare metabolic disease. The MULBERRY trial in treatment-naïve paediatric patients demonstrated statistically significant and clinically meaningful improvements in bone health, while the CHESTNUT trial showed efzimfotase alfa was well-tolerated and maintained therapeutic benefit in paediatric patients switching from Strensiq. Although the HICKORY trial in adole</description>
</item>
<item>
<title>Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD</title>
<link>https://6ix.com/company/astrazeneca-plc/news/tozorakimab-met-primary-endpoint-in-both-oberon-and-titania-phase-iii-trials-in-patients-with-copd</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/tozorakimab-met-primary-endpoint-in-both-oberon-and-titania-phase-iii-trials-in-patients-with-copd</guid>
<pubDate>Fri, 27 Mar 2026 11:00:00 GMT</pubDate>
<description>WILMINGTON, Del., March 27, 2026--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Tozor</description>
</item>
<item>
<title>Tozorakimab met OBERON/TITANIA primary endpoints</title>
<link>https://6ix.com/company/astrazeneca-plc/news/tozorakimab-met-oberontitania-primary-endpoints</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/tozorakimab-met-oberontitania-primary-endpoints</guid>
<pubDate>Fri, 27 Mar 2026 07:00:00 GMT</pubDate>
<description>AstraZeneca PLC announced positive high-level results from its Phase III OBERON and TITANIA trials for tozorakimab in patients with COPD, demonstrating statistically significant and clinically meaningful reductions in exacerbations compared to placebo across various patient subgroups. Tozorakimab, a first-in-class IL-33 targeting biologic, was generally well tolerated and showed a favourable safety profile. These results represent a significant advancement in COPD treatment, addressing a major u</description>
</item>
<item>
<title>Notification of Admission of Shares</title>
<link>https://6ix.com/company/astrazeneca-plc/news/notification-of-admission-of-shares</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/notification-of-admission-of-shares</guid>
<pubDate>Fri, 20 Mar 2026 11:00:00 GMT</pubDate>
<description>AstraZeneca PLC has announced the admission of 45,750 further ordinary shares of $0.25 each to trading on the London Stock Exchange's Main Market. These shares, fully fungible with existing ordinary shares, were issued between January 20, 2026, and March 19, 2026, under the company's employee share schemes and were admitted under a block admission dated January 29, 2021. Following this admission, the total number of ordinary shares in issue is now 1,550,980,332.
Disclaimer*</description>
</item>
<item>
<title>UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer</title>
<link>https://6ix.com/company/astrazeneca-plc/news/uk-first-ai-case-finding-pathway-launched-to-improve-early-detection-of-oesophageal-and-gastric-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/uk-first-ai-case-finding-pathway-launched-to-improve-early-detection-of-oesophageal-and-gastric-cancer</guid>
<pubDate>Thu, 19 Mar 2026 08:30:00 GMT</pubDate>
<description>LONDON, March 19, 2026--A new NHS-first, AI-enabled case-finding pathway has launched across North East Essex, aiming to improve the early detection of Oesophageal and stomach cancers, some of the hardest cancers to diagnose early and among those with the poorest outcomes in England.</description>
</item>
<item>
<title>Imfinzi approved in EU for early gastric cancer</title>
<link>https://6ix.com/company/astrazeneca-plc/news/imfinzi-approved-in-eu-for-early-gastric-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/imfinzi-approved-in-eu-for-early-gastric-cancer</guid>
<pubDate>Mon, 16 Mar 2026 07:00:00 GMT</pubDate>
<description>AstraZeneca's Imfinzi, in combination with FLOT chemotherapy, has received European Union approval as the first and only perioperative immunotherapy for early-stage gastric and gastroesophageal junction cancers, based on the MATTERHORN Phase III trial. This regimen, involving pre- and post-surgery treatment, demonstrated a statistically significant 22% reduction in the risk of death compared to chemotherapy alone, with an estimated 69% of patients alive at three years. The trial also showed a 29</description>
</item>
<item>
<title>Saphnelo (AstraZeneca) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/astrazeneca-plc/news/saphnelo-astrazeneca-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/saphnelo-astrazeneca-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 11:13:00 GMT</pubDate>
<description>Key market opportunities for Saphnelo include the rise of precision immunology treatments, adoption of biologics, and digital disease monitoring. Expansion in healthcare infrastructure, regulatory approvals, and addressing tariffs can support growth. The focus is on advanced therapies and flare prevention strategies.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Saphnelo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's</description>
</item>
<item>
<title>AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer</title>
<link>https://6ix.com/company/astrazeneca-plc/news/astrazeneca-and-joshua-jackson-partner-to-encourage-fans-to-get-body-checked-against-cancer-5</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/astrazeneca-and-joshua-jackson-partner-to-encourage-fans-to-get-body-checked-against-cancer-5</guid>
<pubDate>Tue, 10 Mar 2026 12:30:00 GMT</pubDate>
<description>WILMINGTON, Del., March 10, 2026--AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proactive in speaking with their doctor. Joshua Jackson brings a unique cultural relevance to the initiative, resonating with a generation that grew up watching him on screen and is now entering a life stage where conversations about cancer risk and screenings become increasingly important.</description>
</item>
<item>
<title>ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer</title>
<link>https://6ix.com/company/astrazeneca-plc/news/enhertur-fam-trastuzumab-deruxtecan-nxki-granted-priority-review-in-the-us-as-post-neoadjuvant-treatment-for-patients-with-her2-positive-early-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/enhertur-fam-trastuzumab-deruxtecan-nxki-granted-priority-review-in-the-us-as-post-neoadjuvant-treatment-for-patients-with-her2-positive-early-breast-cancer</guid>
<pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
<description>WILMINGTON, Del., March 09, 2026--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/astrazeneca-plc/news/total-voting-rights-72</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/total-voting-rights-72</guid>
<pubDate>Mon, 02 Mar 2026 15:00:00 GMT</pubDate>
<description>AstraZeneca PLC has announced that as of February 28, 2026, its issued share capital with voting rights comprises 1,550,966,708 ordinary shares, with no shares held in treasury, resulting in a total of 1,550,966,708 voting rights. This figure serves as the denominator for shareholders to determine notification requirements under the UK Financial Conduct Authority's Disclosure and Transparency Rules regarding their interests in the company.
Disclaimer*</description>
</item>
<item>
<title>AstraZeneca prices a $2bn bond offering</title>
<link>https://6ix.com/company/astrazeneca-plc/news/astrazeneca-prices-a-dollar2bn-bond-offering</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/astrazeneca-prices-a-dollar2bn-bond-offering</guid>
<pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
<description>AstraZeneca Finance LLC, a subsidiary of AstraZeneca PLC, has priced a global bond offering totaling $2 billion, consisting of three tranches with fixed rates of 4.000%, 4.300%, and 4.600%, maturing in 2031, 2033, and 2036 respectively. The net proceeds are intended for general corporate purposes, potentially including refinancing existing debt. This bond issuance is not expected to impact AstraZeneca's 2026 financial guidance.
Disclaimer*</description>
</item>
<item>
<title>Filing of Form 20-F with SEC</title>
<link>https://6ix.com/company/astrazeneca-plc/news/filing-of-form-20-f-with-sec</link>
<guid isPermaLink="true">https://6ix.com/company/astrazeneca-plc/news/filing-of-form-20-f-with-sec</guid>
<pubDate>Wed, 25 Feb 2026 07:00:00 GMT</pubDate>
<description>AstraZeneca PLC announced on February 25, 2026, that it filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission on February 24, 2026. The report is accessible on the SEC and AstraZeneca's websites, and hard copies of the audited financial statements are available upon request.
Disclaimer*</description>
</item>
</channel>
</rss>